Vertex Pharmaceuticals Incorporated (VRTX)
Largest Insider Buys in Sector
VRTX Stock Price History Chart
VRTX Stock Performance
About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation. Its pipeline includes VX-864 for the treatment of AAT deficiency, which is in Phase 2 clinical trial; VX-147 for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases which is in Phase 2 clinical trial; VX- 880, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-548, a NaV1.8 inhibitor for treatments of acute, neuropathic, musculoskeletal pain which is in Phase 2 clinical trial; and CTX001 for the treatment severe SCD and TDT which is in Phase 3 clinical trial. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. It has collaborations with Affinia Therapeutics, Inc.; Arbor Biotechnologies, Inc.; CRISPR Therapeutics AG.; Kymera Therapeutics, Inc.; Mammoth Biosciences, Inc.; Moderna, Inc.; Obsidian Therapeutics, Inc.; and Skyhawk Therapeutics, Inc.; as well as Ribometrix, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany, and X-Chem, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
Insider Activity of Vertex Pharmaceuticals Incorporated
Over the last 12 months, insiders at Vertex Pharmaceuticals Incorporated have bought $0 and sold $114.39M worth of Vertex Pharmaceuticals Incorporated stock.
On average, over the past 5 years, insiders at Vertex Pharmaceuticals Incorporated have bought $4.09M and sold $103.42M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 10,000 shares for transaction amount of $1.96M was made by Kewalramani Reshma (CEO & President) on 2021‑08‑19.
List of Insider Buy and Sell Transactions, Vertex Pharmaceuticals Incorporated
| 2024-06-12 | Sale | Bozic Carmen | EVP and CMO | 2,280 0.0009% | $478.00 | $1.09M | -0.43% | |
| 2024-06-12 | Sale | Atkinson Edward Morrow III | EVP, Chief Technical Ops. Off. | 7,288 0.0028% | $478.00 | $3.48M | -0.43% | |
| 2024-06-03 | Sale | Tatsis Ourania | EVP, Chief Reg. & Quality Off. | 2,175 0.0008% | $460.00 | $1M | +1.14% | |
| 2024-06-03 | Sale | WAGNER CHARLES F JR | EVP & Chief Financial Officer | 3,250 0.0012% | $460.00 | $1.5M | +1.14% | |
| 2024-05-31 | Sale | Tatsis Ourania | EVP, Chief Reg. & Quality Off. | 2,250 0.0009% | $445.00 | $1M | +4.41% | |
| 2024-05-30 | Sale | Tatsis Ourania | EVP, Chief Reg. & Quality Off. | 2,350 0.0009% | $439.11 | $1.03M | +7.22% | |
| 2024-05-29 | Sale | Bozic Carmen | EVP and CMO | 2,280 0.0009% | $445.56 | $1.02M | +7.68% | |
| 2024-05-28 | Sale | WAGNER CHARLES F JR | EVP & Chief Financial Officer | 3,250 0.0013% | $454.79 | $1.48M | +6.20% | |
| 2024-05-24 | Sale | Kewalramani Reshma | CEO & President | 1,565 0.0006% | $457.00 | $715,205 | +3.82% | |
| 2024-05-22 | Sale | SACHS BRUCE I | director | 7,073 0.0027% | $448.00 | $3.17M | +5.85% | |
| 2024-05-20 | Sale | Kewalramani Reshma | CEO & President | 15,202 0.0059% | $447.00 | $6.8M | +5.98% | |
| 2024-05-15 | Sale | Sachdev Amit | EVP Chief Patient & Ext Af Off | 32 <0.0001% | $430.93 | $13,790 | +7.49% | |
| 2024-05-15 | Sale | Arbuckle Stuart A | EVP, COO | 69 <0.0001% | $430.93 | $29,734 | +7.49% | |
| 2024-05-15 | Sale | ALTSHULER DAVID | EVP, Chief Scientific Officer | 54 <0.0001% | $430.93 | $23,270 | +7.49% | |
| 2024-05-02 | Sale | Bhatia Sangeeta N. | director | 467 0.0002% | $402.95 | $188,178 | +13.22% | |
| 2024-04-02 | Sale | Ambrose Kristen | SVP & Chief Accounting Officer | 240 <0.0001% | $419.00 | $100,560 | +4.86% | |
| 2024-02-26 | Sale | Tatsis Ourania | EVP, Chief Reg. & Quality Off. | 354 0.0001% | $425.70 | $150,698 | -3.70% | |
| 2024-02-26 | Sale | Sachdev Amit | EVP Chief Patient & Ext Af Off | 3,004 0.0011% | $425.70 | $1.28M | -3.70% | |
| 2024-02-26 | Sale | Arbuckle Stuart A | EVP, COO | 5,034 0.0019% | $425.70 | $2.14M | -3.70% | |
| 2024-02-26 | Sale | ALTSHULER DAVID | EVP, Global Research and CSO | 4,239 0.0016% | $425.70 | $1.8M | -3.70% |
Insider Historical Profitability
| Kewalramani Reshma | CEO & President | 121374 0.0422% | $474.00 | 1 | 24 | +20.8% |
| Sachdev Amit | EVP Chief Patient & Ext Af Off | 55325 0.0228% | $474.00 | 1 | 103 | +5.21% |
| Arbuckle Stuart A | EVP, COO | 49691 0.0219% | $474.00 | 0 | 101 | |
| Tatsis Ourania | EVP, Chief Reg. & Quality Off. | 49098 0.0189% | $474.00 | 0 | 28 | |
| WAGNER CHARLES F JR | EVP & Chief Financial Officer | 47137 0.017% | $474.00 | 0 | 13 | |
| SACHS BRUCE I | director | 40000 0.0155% | $474.00 | 7 | 32 | +20.85% |
| ALTSHULER DAVID | EVP, Global Research and CSO | 25813 0.0124% | $474.00 | 0 | 85 | |
| Bozic Carmen | EVP and CMO | 32379 0.0114% | $474.00 | 0 | 8 | |
| Atkinson Edward Morrow III | EVP, Chief Technical Ops. Off. | 15972 0.009% | $474.00 | 0 | 5 | |
| Biller Jonathan | EVP and Chief Legal Officer | 18280 0.0041% | $474.00 | 0 | 2 | |
| Ambrose Kristen | SVP & Chief Accounting Officer | 7500 0.0027% | $474.00 | 0 | 6 | |
| Kearney Terrence C | director | 6536 0.0025% | $474.00 | 0 | 4 | |
| Bhatia Sangeeta N. | director | 4435 0.0015% | $474.00 | 0 | 21 | |
| LEIDEN JEFFREY M | Executive Chairman | 17896 0.0009% | $474.00 | 2 | 51 | <0.0001% |
| Vertex Pharmaceuticals (Europe) Ltd | 10 percent owner | 5380940 2.0882% | $474.00 | 4 | 0 | +14.31% |
| BOGER JOSHUA S | director | 268225 0.1041% | $474.00 | 0 | 371 | |
| Emmens Matthew | director | 200873 0.078% | $474.00 | 0 | 3 | |
| MUELLER PETER | EVP, Global R&D, CSO | 143517 0.0557% | $474.00 | 0 | 67 | |
| ALAM JOHN J | EVP, Med. Dev. Group & CMO | 136792 0.0531% | $474.00 | 0 | 31 | |
| BOGER KENNETH S | SVP & Chief Legal Officer | 112999 0.0439% | $474.00 | 1 | 19 | +11.48% |
| SATO VICKI L | President | 108108 0.042% | $474.00 | 0 | 74 | |
| Hartmann Victor A | EVP, Strategic & Corp. Devlp. | 97273 0.0377% | $474.00 | 0 | 10 | |
| Chodakewitz Jeffrey | EVP GMDA, CMO | 69663 0.027% | $474.00 | 0 | 33 | |
| Graves Kurt | EVP, Chief Commercial Officer | 59880 0.0232% | $474.00 | 1 | 11 | +4.03% |
| Lewis-Hall Freda C | EVP, Medicines Development | 53334 0.0207% | $474.00 | 0 | 4 | |
| SMITH IAN F | EVP, COO | 46699 0.0181% | $474.00 | 0 | 66 | |
| BRUM LYNNE H | VP, Strategic Communications | 46199 0.0179% | $474.00 | 0 | 18 | |
| Pace Megan E | SVP, Corp. Communications | 43350 0.0168% | $474.00 | 0 | 12 | |
| Stamoulis Christiana | SVP, Corp Strategy & Bus Devlp | 40712 0.0158% | $474.00 | 0 | 5 | |
| GARRISON RICHARD C | SVP and Catalyst | 37473 0.0145% | $474.00 | 0 | 8 | |
| Connolly Thomas | SVP, Human Resources | 34375 0.0133% | $474.00 | 0 | 12 | |
| Horton Kenneth L | EVP & Chief Legal Officer | 32463 0.0126% | $474.00 | 0 | 4 | |
| Wysenski Nancy | EVP, Chief Commercial Officer | 32232 0.0125% | $474.00 | 0 | 6 | |
| Sanna Bastiano | EVP, Cell & Genetic Therapies | 32038 0.0124% | $474.00 | 0 | 23 | |
| Parini Michael | EVP, Chief Adm, Leg & BD Off | 30837 0.012% | $474.00 | 0 | 63 | |
| SANDERS CHARLES A | director | 26383 0.0102% | $474.00 | 1 | 14 | +17.85% |
| Kelly Lisa | SVP, Human Resources | 15216 0.0059% | $474.00 | 0 | 28 | |
| Liu Joy | SVP, General Counsel | 12448 0.0048% | $474.00 | 0 | 7 | |
| Graney Thomas | Chief Financial Officer | 12430 0.0048% | $474.00 | 0 | 2 | |
| CORDES EUGENE | director | 12000 0.0047% | $474.00 | 0 | 3 | |
| Silva Paul M | SVP & Chief Accounting Officer | 9884 0.0038% | $474.00 | 0 | 116 | |
| Howton David T | SVP | 9271 0.0036% | $474.00 | 0 | 1 | |
| YOUNG WILLIAM D | director | 9311 0.0036% | $474.00 | 0 | 2 | |
| WINGER DENNIS L | director | 6500 0.0025% | $474.00 | 1 | 0 | <0.0001% |
| POWER JOHANNA MESSINA | VP & Controller | 6555 0.0025% | $474.00 | 0 | 56 | |
| ULLIAN ELAINE | director | 5265 0.002% | $474.00 | 3 | 15 | +46.27% |
| CARNEY LLOYD | director | 4150 0.0016% | $474.00 | 0 | 1 | |
| COLLINSON STUART J | director | 3279 0.0013% | $474.00 | 0 | 7 | |
| BUCHANAN IAIN P M | VP, European Operations | 2094 0.0008% | $474.00 | 0 | 6 | |
| Lee Yuchun | director | 1875 0.0007% | $474.00 | 0 | 31 | |
| MCGLYNN MARGARET G | 1099 0.0004% | $474.00 | 1 | 12 | +64.36% | |
| Slater Eve Elizabeth | director | 1105 0.0004% | $474.00 | 2 | 1 | +1.76% |
| Riley Wayne Joseph | director | 400 0.0002% | $474.00 | 0 | 6 | |
| BRANDT ERIC | director | 0 0% | $474.00 | 0 | 1 | |
| BRIMBLECOMBE ROGER W | director | 0 0% | $474.00 | 0 | 6 |
Institutional Investor Ownership
| Capital World Investors | $10.69B | 9.91 | 25.57M | +17.25% | +$1.57B | 1.77 | |
| The Vanguard Group | $9.48B | 8.79 | 22.68M | +1.77% | +$164.84M | 0.18 | |
| BlackRock | $9.18B | 8.51 | 21.96M | +0.36% | +$33.23M | 0.21 | |
| State Street | $5.02B | 4.65 | 12.01M | -0.64% | -$32.33M | 0.22 | |
| Fidelity Investments | $4.46B | 4.14 | 10.67M | -17.77% | -$963.93M | 0.3 | |
| AllianceBernstein | $2.97B | 2.75 | 7.1M | +0.82% | +$24.05M | 1.05 | |
| JPMorgan Chase | $2.52B | 2.33 | 6.02M | +7% | +$164.64M | 0.23 | |
| Geode Capital Management | $2.42B | 2.25 | 5.81M | +2.46% | +$58.23M | 0.22 | |
| Capital Research Global Investors | $2.4B | 2.23 | 5.74M | +61% | +$909.68M | 0.54 | |
| JENNISON ASSOCIATES LLC | $2B | 1.85 | 4.78M | +21.23% | +$350.07M | 1.34 | |
| Wellington Management Company | $1.91B | 1.77 | 4.56M | -12.82% | -$280.19M | 0.32 | |
| T. Rowe Price | $1.88B | 1.74 | 4.49M | -23.68% | -$582.7M | 0.23 | |
| Amundi | $1.41B | 1.39 | 3.58M | +31.82% | +$340.99M | 0.59 | |
| Morgan Stanley | $1.33B | 1.23 | 3.18M | +6.84% | +$85.28M | 0.1 | |
| Loomis, Sayles & Company | $1.3B | 1.21 | 3.11M | -0.78% | -$10.21M | 1.88 | |
| Massachusetts Financial Services Co Ma | $1.17B | 1.09 | 2.8M | -22.66% | -$343.44M | 0.35 | |
| Janus Henderson | $1.08B | 1 | 2.58M | +10.44% | +$102.14M | 0.59 | |
| Northern Trust | $1.08B | 1 | 2.58M | -3.81% | -$42.7M | 0.18 | |
| Bank of America | $1.06B | 0.99 | 2.54M | +4.46% | +$45.45M | 0.1 | |
| Ubs Asset Management Americas Inc | $1.02B | 0.95 | 2.45M | -5.92% | -$64.31M | 0.36 | |
| ClearBridge Investments | $1.02B | 0.94 | 2.43M | -6.33% | -$68.6M | 0.81 | |
| Legal & General | $1B | 0.93 | 2.39M | -1.53% | -$15.5M | 0.24 | |
| Ameriprise Financial | $930.11M | 0.86 | 2.23M | -11.34% | -$119.01M | 0.26 | |
| Invesco | $874.12M | 0.81 | 2.09M | -6.73% | -$63.1M | 0.18 | |
| BNY Mellon | $783.4M | 0.73 | 1.87M | -5.2% | -$43M | 0.15 | |
| Renaissance Technologies | $660.66M | 0.61 | 1.58M | -0.7% | -$4.68M | 1.05 | |
| Deutsche Bank | $659.14M | 0.61 | 1.58M | -4.24% | -$29.18M | 0.3 | |
| Charles Schwab | $650.68M | 0.6 | 1.56M | +3.14% | +$19.82M | 0.15 | |
| Royal Bank of Canada | $643.87M | 0.6 | 1.54M | +5.9% | +$35.89M | 0.15 | |
| Goldman Sachs | $585.62M | 0.54 | 1.4M | -5.66% | -$35.1M | 0.11 | |
| Harding Loevner LP | $511.23M | 0.47 | 1.22M | -7.43% | -$41.04M | 3.16 | |
| CalPERS | $493.4M | 0.46 | 1.18M | -22.13% | -$140.23M | 0.35 | |
| Voya Investment Management LLC | $392.31M | 0.36 | 939,426 | +21.14% | +$68.46M | 0.44 | |
| De Depot Et Placement Du Quebec Caisse | $357.44M | 0.33 | 855,109 | +6.39% | +$21.48M | 0.86 | |
| Nuveen | $349.34M | 0.32 | 835,717 | -0.64% | -$2.26M | 0.1 | |
| Barclays | $341.69M | 0.32 | 817,415 | +1.32% | +$4.45M | 0.16 | |
| HSBC | $336.84M | 0.31 | 805,942 | +31.12% | +$79.94M | 0.24 | |
| Swiss National Bank | $322.58M | 0.3 | 771,700 | -4.39% | -$14.8M | 0.22 | |
| Wells Fargo | $320.85M | 0.3 | 767,567 | +2.48% | +$7.78M | 0.09 | |
| Sumitomo Mitsui Trust Holdings | $300.3M | 0.28 | 718,410 | +1.1% | +$3.26M | 0.21 | |
| Franklin Templeton Investments | $293.89M | 0.27 | 703,059 | +4.55% | +$12.8M | 0.09 | |
| The Manufacturers Life Insurance Company | $290.86M | 0.27 | 695,825 | -15.02% | -$51.41M | 0.26 | |
| American Century Investments | $290.47M | 0.27 | 694,894 | -13.2% | -$44.16M | 0.18 | |
| Bellevue Group | $279.54M | 0.26 | 668,750 | -9.19% | -$28.27M | 4.26 | |
| AQR Capital | $278.68M | 0.26 | 666,691 | +3.4% | +$9.16M | 0.47 | |
| Dimensional Fund Advisors | $245.75M | 0.23 | 587,912 | +0.46% | +$1.13M | 0.07 | |
| Standard Life | $240.02M | 0.22 | 574,197 | -1.17% | -$2.85M | 0.47 | |
| UBS | $239.18M | 0.22 | 572,180 | +35.04% | +$62.06M | 0.07 | |
| Qube Research & Technologies | $233.47M | 0.22 | 558,536 | +20.11% | +$39.09M | 0.28 | |
| Artisan Partners | $231.11M | 0.21 | 552,882 | -4.1% | -$9.88M | 0.34 |